Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Powles, Thomas; Csőszi, Tibor; Özgüroğlu, MUSTAFA; Matsubara, Nobuaki; Géczi, Lajos; Cheng, Susanna; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Morales Barrera, Rafael; Fléchon, Aude; Gunduz, Seyda; Loriot, Yohann; Rodriguez-Vida, Alejo; Mamtani, Ronac; Yu, Evan; Nam, Kijoeng; Imai, Kentaro; Homet Moreno, Blanca; Alva, Ajjai

doi:10.1016/s1470-2045(21)00152-2

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Powles T., Csőszi T., Özgüroğlu M., Matsubara N., Géczi L., Cheng S. Y., ...Daha Fazla

The Lancet. Oncology, cilt.22, ss.931-945, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22
Basım Tarihi: 2021
Doi Numarası: 10.1016/s1470-2045(21)00152-2
Dergi Adı: The Lancet. Oncology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.931-945
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.